Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of HCP1102 Capsule

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Age≥15~* Mild or moderate asthma patients with allergic rhinitis~* Patient who meet all criteria of rhinitis~* Patients understood the contents and purpose of this trial and signed informed consent form~* Patients who are capable and willing to write subject diary~* Patients who agree with maintain same environment during clinical trials~Exclusion:~* Nonallergic rhinitis~* Severe asthma~* Other pulmonary disease (pulmonary tuberculosis, COPD) except Asthma~* Medical history of hypertrophic cardiomyopathy, cancer, renal disease, Liver disease, cardiovascular disease, respiratory disease, endocrine disorder, CNS disorder that effect safety~* Medical history of gastrointestinal surgery or gastrointestinal disorders that effect drug absorption~* Alcohol abuse or Drug abuse~* Genetic factor of galactose intolerance or Lapp lactase deficiency or glucose-galactose malabsorption~* pregnant or breast-feeding women or men/women of childbearing age that they don't use contraceptives~* Patient who administered other investigational products within 30 days~* Current smoker Judged to be inappropriate for the study by the investigator after reviewing other reasons

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HCP1102+HGP0711Placebo (Type: EXPERIMENTAL): HCP1102Placebo+HGP0711Placebo(1week) -\> HCP1102+HGP0711Placebo(4weeks) Each 1 capsule, once daily
- HCP1102Placebo+HGP0711 (Type: ACTIVE_COMPARATOR): HCP1102Placebo+HGP0711Placebo(1week) -\> HCP1102Placebo+HGP0711(4weeks) Each 1 capsule, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).